Razzaki Tanzila S, Weiner Alyson, Shukla Alpana P
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA.
Ther Clin Risk Manag. 2022 Sep 28;18:955-964. doi: 10.2147/TCRM.S328056. eCollection 2022.
Tirzepatide is a novel "twincretin" with glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist activity, which was recently approved by the Food and Drug Administration for the treatment of type 2 diabetes mellitus. In this review, we discuss preclinical and mechanistic human studies, which demonstrate improvements in insulin sensitivity and beta-cell function with the use of tirzepatide, as compared to placebo and glucagon-like peptide 1 receptor agonists. We then discuss SURPASS trials 1-5, which evaluated the safety and efficacy of tirzepatide for type 2 diabetes mellitus as either monotherapy or combination therapy with other antidiabetic agents. The magnitude of tirzepatide's effects and the efficacy relative to other anti-diabetes medications on weight, glycemic control, and beta-cell function may prove beneficial for the treatment of early type 2 diabetes mellitus. Further studies, including data on cardiovascular outcomes and long-term safety, will continue to elucidate the role of tirzepatide in the treatment algorithm of type 2 diabetes mellitus.
替尔泊肽是一种新型的“双肠促胰岛素”，具有胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽受体激动剂活性，最近已获美国食品药品监督管理局批准用于治疗2型糖尿病。在这篇综述中，我们讨论了临床前和人体机制研究，这些研究表明，与安慰剂和胰高血糖素样肽-1受体激动剂相比，使用替尔泊肽可改善胰岛素敏感性和β细胞功能。然后，我们讨论了SURPASS试验1-5，这些试验评估了替尔泊肽作为单一疗法或与其他抗糖尿病药物联合疗法治疗2型糖尿病的安全性和有效性。替尔泊肽的作用程度以及相对于其他抗糖尿病药物在体重、血糖控制和β细胞功能方面的疗效，可能对早期2型糖尿病的治疗有益。包括心血管结局数据和长期安全性数据在内的进一步研究，将继续阐明替尔泊肽在2型糖尿病治疗方案中的作用。
